Julia James Appointed Clario Chief Legal and Administrative Officer

Julia James

Clario, a healthcare research and technology company that delivers the leading endpoint technology solutions for clinical trials, today announced the appointment of Julia James as the company’s Chief Legal and Administrative Officer. This appointment bolsters Clario’s strategic focus on improving the customer experience and differentiating its offerings.

Chris Fikry, M.D., Chief Executive Officer at Clario

“We are excited to welcome Julia James to Clario. Her extensive legal and compliance expertise will help us continue to advance Clario’s impact in clinical trials, further enhancing our efforts on quality and speed to empower our partners to transform lives.”

Past Experience

Julia James served as Executive Vice President and General Counsel of PPD, the leading contract research organization, until its acquisition by Thermo Fisher Scientific in 2021. She then continued as General Counsel, Clinical Research, following the transaction. Julia spent more than 15 years in various legal leadership roles at PPD and, prior to that, worked for the international law firm Clifford Chance in both London and Dubai. She is passionate about empowering women in business to succeed individually and collectively.

“Clario plays a pivotal role in the clinical trial ecosystem through the generation of the highest quality evidence and developing transformative technologies,” she said. “It is a privilege to have the opportunity to join such a high-performing team focused on improving the health of patients around the world.”

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.